October 1, 2012 — Effective immediately, Ziehm Imaging, a market leader for mobile C-arms, is offering operating room (OR) tables from the Swedish manufacturer Stille to complement its Ziehm Vision RFD Hybrid Edition.

October 1, 2012 — Bristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the new drug application (NDA) resubmission for Eliquis (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).

October 1, 2012 — SunTech Medical’s One-Piece Durable Cuffs are a new line of easily disinfected, reusable cuffs for reliable blood pressure monitoring. The highly durable cuffs feature a cost-effective, one-piece design sturdy enough for repeated use in any clinical environment.

October 1, 2012 — CircuLite Inc. announced that the latest data from patients enrolled in the company’s CE mark trial of the Synergy Circulatory Support System strengthened prior findings indicating that implantation with Synergy resulted in significant, sustained improvements in hemodynamics and exercise tolerance.

September 28, 2012 — MindChild Medical Inc. announced that it has received 510(k) premarketing notification clearance from the U.S. Food and Drug Administration (FDA) for its Meridian noninvasive fetal heart monitor, and anticipates entering the U.S. market with Meridian soon. Additional pre-market regulatory filings are anticipated during 2012 and 2013.

September 28, 2012 — Accumetrics Inc., developer of the VerifyNow System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced the launch of its Quality Improvement and Value Assessment Program.

Abbott Bioabsorbable Stent Absorb

The world’s first drug-eluting bioabsorbable vascular scaffold has been launched and will revolutionize the stent industry. On Sept. 25, 2012, Abbott announced the launch of its drug-eluting bioabsorbable stent, Absorb, in Europe, the Middle East and parts of Asia Pacific and Latin America. Absorb, which received CE mark certification in 2011, is used to treat coronary artery disease. Bioabsorbable stents, such as Absorb, will broaden treatment and diagnostic options, reduce the need for long-term anti-platelet therapy and reduce the risk of in-stent restenosis and thrombosis.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now